comparemela.com

Latest Breaking News On - Alain moussy - Page 1 : comparemela.com

AB Science: upbeat after legal success - MarketScreener

AB Science is up over 5% after the pharmaceutical company announced that it had successfully appealed to the Paris Court of Appeal against the decision of the AMF s Enforcement Committee on March 24,.

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

PRESS RELEASE THE PARIS COURT OF APPEAL CONFIRMS THE ACQUITTAL OF THE CEO OF AB SCIENCE, ALAIN MOUSSY, AND REDUCES THE AMOUNT OF THE FINANCIAL PENALTY IMPOSED ON AB SCIENCE Paris, May 2, 2024, 7pm.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease -March 13, 2024 at 08:00 am EDT

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM.

AB Science: medical use patent for masitinib -January 15, 2024 at 12:41 pm EST

AB Science has announced that the European Patent Office has issued a Notice of Allowance for a method patent for the treatment of severe systemic mastocytosis with its lead compound, masitinib. This.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.